CWY | Jotup

Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures

Retrieved on:

월요일, 11월 27, 2023

MEAI, MSW, MAPS, CWY, Doctor of Philosophy, Drug policy, Therapy

Tel Aviv, Israel / Vancouver, Canada, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, will participate in a special virtual event to discuss the current psychedelic renaissance that is opening the doors to the benefits of both traditional and novel psychedelics, as older therapies are being re-examined and new molecules are being identified for current and future clinical studies.

Key Points:

The virtual event will be held on Wednesday, Nov 29, 2023 at 12pm EST/ 9am PST.
The virtual event is part of The Psychedelic Association of Canada (PAC) "Industry Presents" Series.
Clearmind's CEO, Adi Zuloff-Shani, PhD, will share her thoughts about the Company's innovative MEAI molecule, defined as novel psychedelics.
Mark Haden, MSW, VP of business development for Clearmind Medicine, will take part in the event as well.

Clearmind Medicine Announces 1-for-30 Reverse Share Split

Retrieved on:

화요일, 11월 21, 2023

Indian stock exchange, CWY, Therapy, Exercise

Tel Aviv, Israel / Vancouver, Canada, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced it will conduct a reverse share split of its issued and outstanding ordinary shares, no par value, at a ratio of 1-for-30. The reverse split is being effected as part of the Company’s plan to regain compliance with the Nasdaq Minimum Bid Price Rule and will be effective commencing November 28, 2023.

Key Points:

Following the reverse share split, the Company will have 607,381 Ordinary Shares issued and outstanding
Tel Aviv, Israel / Vancouver, Canada, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced it will conduct a reverse share split of its issued and outstanding ordinary shares, no par value, at a ratio of 1-for-30.
The reverse share split was approved by the Company’s shareholders at the Company’s general shareholders meeting held on November 14, 2023 and subsequently resolved by the Company' board of directors.
Following the implementation of the reverse split, the Company’s authorized share capital will remain unchanged, which as of the date hereof is unlimited.
No fractional Common Shares will be issued as a result of the reverse split.

Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance

Retrieved on:

금요일, 11월 17, 2023

FSE, CSE, Form, Therapy, Failure, CWY, Auction

Tel Aviv, Israel / Vancouver, Canada, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced receipt of a Staff Delisting Determination (the "Staff Determination") from the Listing Qualifications Department of the Nasdaq Stock Market, LLC ("Nasdaq"). The Company was notified that Nasdaq has determined to delist the Company's securities from the Nasdaq Capital Market for failure to maintain a minimum bid price of $1.00 per share for thirty consecutive business days in accordance with Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule").

Key Points:

As part of the Company’s plan for recompliance, the Company’s shareholders approved a reverse stock split on November 14, 2023.
Tel Aviv, Israel / Vancouver, Canada, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced receipt of a Staff Delisting Determination (the "Staff Determination") from the Listing Qualifications Department of the Nasdaq Stock Market, LLC ("Nasdaq").
On November 14th, the Company’s shareholders approved a reverse stock split, which the Company expects will be made effective imminently.
“We are looking forward to updating our shareholders regarding the Company’s compliance with the Minimum Bid Price Rule soon.”

Clearmind Medicine Announces Shareholders Meeting Results

Retrieved on:

수요일, 11월 15, 2023

FSE, Therapy, Meeting, CSE, CWY, Holding company

Tel Aviv, Israel / Vancouver, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce that all of the matters put forward before shareholders for consideration and approval at its meeting held on November 14, 2023 (the “Meeting”), as set out in the Company’s Management Information Circular dated October 9, 2023, were approved by the requisite majority of votes cast at the Meeting, including a resolution fixing the board of directors at four members, the election of directors of the Company for the ensuing year, a resolution to establish and approve an omnibus equity incentive plan and a resolution approving the directors to effect a consolidation (the “Consolidation”) of the common shares in the capital of the Company (the “Shares”) on the basis of fifty (50) pre-Consolidation Shares for one (1) post-Consolidation Share, or such other lesser consolidation ratio as determined by the Company’s board of directors at its sole discretion, in one or more tranches during the twelve (12) months immediately following the Meeting.

Key Points:

Tel Aviv, Israel / Vancouver, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce that all of the matters put forward before shareholders for consideration and approval at its meeting held on November 14, 2023 (the “Meeting”), as set out in the Company’s Management Information Circular dated October 9, 2023, were approved by the requisite majority of votes cast at the Meeting, including a resolution fixing the board of directors at four members, the election of directors of the Company for the ensuing year, a resolution to establish and approve an omnibus equity incentive plan and a resolution approving the directors to effect a consolidation (the “Consolidation”) of the common shares in the capital of the Company (the “Shares”) on the basis of fifty (50) pre-Consolidation Shares for one (1) post-Consolidation Share, or such other lesser consolidation ratio as determined by the Company’s board of directors at its sole discretion, in one or more tranches during the twelve (12) months immediately following the Meeting.

Clearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th

Retrieved on:

목요일, 10월 5, 2023

Therapy, CSE, FSE, CWY, Conference, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, will be participating in the 8th Annual Dawson James Conference on Thursday, October 12th, 2023, at the Wyndam Grand Jupiter at Harbourside Place, in Jupiter Florida.

Key Points:

Tel Aviv, Israel / Vancouver, Canada, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, will be participating in the 8th Annual Dawson James Conference on Thursday, October 12th, 2023, at the Wyndam Grand Jupiter at Harbourside Place, in Jupiter Florida.
Presentation details are as follows:
Location: Wyndham Grand Jupiter at Harbourside Place, in Jupiter, Florida
Management will be participating in one-on-one meetings with qualified members of the investor community throughout the conference.
To request a meeting, please contact [email protected].

Clearmind Medicine to Present at the LD Micro Main Event XVI Investor Conference on October 4th

Retrieved on:

목요일, 9월 28, 2023

CSE, Therapy, FSE, CWY, Conference, Pharmaceutical industry

Tel Aviv, Israel and Vancouver, British Columbia--(Newsfile Corp. - September 28, 2023) - Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND) (FSE: CWY) ("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, will be participating in the LD Micro Main Event XVI Conference, being held October 3-5, 2023, at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

Key Points:

Tel Aviv, Israel and Vancouver, British Columbia--(Newsfile Corp. - September 28, 2023) - Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND) (FSE: CWY) ("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, will be participating in the LD Micro Main Event XVI Conference, being held October 3-5, 2023, at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
Presentation details are as follows:
Dr. Adi Zuloff-Shani will also be hosting one-on-one meetings with investors on October 4, 2023.
Investors interested in arranging a meeting should contact their conference representative.

Clearmind Medicine Closes US$2.25 Million Public Offering

Retrieved on:

월요일, 9월 18, 2023

CSE, Therapy, Telephone, CAD, SEC filing, FSE, Research, Sale, Prospectus, CWY, Form, Security (finance)

The offering consisted of 7,500,000 common shares and pre-funded warrants and 7,500,000 common warrants.

Key Points:

The offering consisted of 7,500,000 common shares and pre-funded warrants and 7,500,000 common warrants.
The common warrants are immediately exercisable, will expire five years from the date of issuance and will have an exercise price of US$0.30 (CAD$0.40) per common share.
The offering was not made in Canada and residents of Canada did not purchase any securities in the offering.
333-273293) relating to the offering of the securities was filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on September 14, 2023.

Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering

Retrieved on:

목요일, 9월 14, 2023

CSE, Therapy, Telephone, SEC filing, FSE, Research, Sale, Prospectus, CWY, Form, Security (finance)

The offering consists of 7,500,000 common shares and pre-funded warrants and 7,500,000 common warrants.

Key Points:

The offering consists of 7,500,000 common shares and pre-funded warrants and 7,500,000 common warrants.
The common warrants are immediately exercisable, will expire five years from the date of issuance and will have an exercise price of US$ 0.30 per common share.
The offering is expected to close on September 18, 2023, subject to the satisfaction of customary closing conditions.
The offering is not being made in Canada and residents of Canada may not purchase any securities being offered in the offering.

Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder

Retrieved on:

수요일, 9월 6, 2023

"We are honored to collaborate with JHU for our first in human clinical trial.

Key Points:

"We are honored to collaborate with JHU for our first in human clinical trial.
"Johns Hopkins is our second US clinical site joining our trial, following Yale School of Medicine’s Department of Psychiatry.
The patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period.
CM-CMND-001 clinical trial is a multinational, multi-center, Phase I/II single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD subjects.

Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company

Retrieved on:

월요일, 8월 14, 2023

CSE, Therapy, Marketing, FSE, Research, CTS, CWY, Health, Mental health, Safety, Pharmaceutical industry

CTS is a leading pharmaceutical and consumer products company in Israel.

Key Points:

CTS is a leading pharmaceutical and consumer products company in Israel.
Founded in 1921, CTS focuses on solutions that have clinically proven efficacy and safety, supporting the health of people.
In addition, CTS imports, registers, markets, and distributes healthcare products of leading global pharmaceutical companies across Israel.
As part of the collaboration, Clearmind Medicine will have access to the CTS’ state-of-the-art facilities, allowing it to expand its research and development capabilities.